GlaxoSmithKline - AGM 08 May 2019
The AGM is followed by an EGM to be held at 15:30 in the same location.
AGM Item 2: Approve the Remuneration Report
The remuneration structure is unsatisfactory. The main concern is the potential for excessive incentive pay with a maximum of 850% of base salary. In addition, the use of qualitative criteria exceeds guidelines and accelerated vesting is possible. The quantum for the year is also considered excessive. We recommend shareholders oppose.
EGM Item 1: To approve the transaction between GlaxoSmithKline Consumer Healthcare Holdings Ltd and Pfizer Inc
The Company is seeking shareholder approval of a related party transaction, whereby a Company subsidiary will enter into a joint venture with Pfizer Inc (“Pfizer”)The proposed joint venture will combine the two groups' consumer healthcare businesses. The Board states that the transaction will benefit the Company through a strong brand portfolio, leadership positions in key geographic areas, scale and innovation, and cost synergies. They also note that the management team has experience integrating businesses.
On completion, the Company will own a majority controlling equity interest of 68% and the Pfizer Group will own the remaining 32% of the joint venture. Ultimately, the intention is to list the joint venture separately. However, this would be conditional upon shareholder approval at that time.
As no governance concerns have been identified, the Board has presented a strategic justification for the proposed joint venture and separate shareholder approval would be sought for the spin-off should it occur, we recommend shareholders vote in favor.
GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.